<bill session="118" type="h" number="4242" updated="2024-07-24T15:21:19Z">
  <state datetime="2023-06-21">REFERRED</state>
  <status>
    <introduced datetime="2023-06-21"/>
  </status>
  <introduced datetime="2023-06-21"/>
  <titles>
    <title type="display">To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy.</title>
    <title type="official" as="introduced">To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy.</title>
  </titles>
  <sponsor bioguide_id="C001120"/>
  <cosponsors>
    <cosponsor bioguide_id="K000389" joined="2023-06-21"/>
    <cosponsor bioguide_id="M001215" joined="2023-06-21"/>
  </cosponsors>
  <actions>
    <action datetime="2023-06-21">
      <text>Introduced in House</text>
    </action>
    <action datetime="2023-06-21" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2023-06-23">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Alternative treatments"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug therapy"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Medical research"/>
  </subjects>
  <amendments/>
  <summary date="2024-07-19T19:39:44Z" status="Introduced in House">This bill requires the Food and Drug Administration (FDA) to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy, including how to request support from the FDA for related investigational use exemptions.</summary>
</bill>
